Table 3 Simple Cox analysis indicating risk factors for P. aeruginosa respiratory infection and/or colonization

Female sex

62

4 (6.5%)

0.71

0.23–2.15

0.54

Absence of probiotic

106

13 (12.3%)

3.31

1.17–9.40

0.024

Hospitalization duration < 15 days

107

4 (3.7%)

0.59

0.15–2.34

0.45

SAPS II score < 43

105

6 (5.7%)

0.69

0.26–1.85

0.46

Traumatology and surgical pathology

126

11 (8.7%)

0.97

0.38–2.51

0.95

Underlying respiratory tract disease

33

5 (15.2%)

1.63

0.58–4.58

0.35

Amoxicillin/clavulanate

120

13 (10.8%)

0.41

0.14–1.20

0.10

Piperacillin + tazobactam

21

3 (14.3%)

1.24

0.36–4.33

0.73

Cefotaxime

54

7 (13.0%)

1.15

0.44–3.01

0.77

Cefepime

42

6 (14.3%)

1.03

0.38–2.80

0.96

Ceftazidime

33

7 (21.2%)

1.59

0.59–4.27

0.35

Imipenem

30

6 (20.0%)

1.05

0.36–3.03

0.93

Aminoglycosides

20

1 (5.0%)

0.28

0.04–2.14

0.22

Ciprofloxacin

74

8 (10.8%)

0.59

0.22–1.59

0.30

Quinolones

138

14 (10.1%)

0.66

0.21–2.09

0.48

Glycopeptides

59

10 (16.9%)

1.42

0.54–3.76

0.47

Fluconazole

71

8 (11.3%)

0.56

0.21–1.50

0.25

Enterobacteriaceae infection/colonization

91

9 (9.9%)

0.88

0.35–2.24

0.79

Candida respiratory tract colonization

20

2 (10.0%)

0.60

0.13–2.65

0.50

S. aureus respiratory tract infection/colonization

39

8 (20.5%)

1.69

0.65–4.39

0.28